Objective: In this work, we aim to synthesize gallic acid derivatives with chiral center and to evaluate its anti-hepatitis C virus (anti-HCV) activity.
INTRODUCTION
Hepatitis C is an infectious disease caused by hepatitis C virus (HCV) that attacks the liver, causing inflammation to damage the liver cells. Hepatitis C has become a global health issue since the World Health Organization estimated that about 170 million of the world's population is currently suffering in hepatitis C. The prevalence of HCV infection varies worldwide. Endemic areas are quite high among Southeast Asia, including in Indonesia, with 7 million people are infected by hepatitis C [1] [2] [3] . Various therapies have been applied for the treatment of HCV infections, including the use of combination therapy with interferon alpha or pegylated interferon as an immunomodulator, with Ribavirin, boceprevir or telaprevir as an antiviral nucleoside analog, which is effective to inhibit the growth of cells of hepatitis C [4] [5] [6] [7] . Polamreddy et al. reported that until 2011, the standard treatment for hepatitis C was with a combination of pegylated interferon and Ribavirin which is given for period from 24 to 48 weeks. However, this treatment showed severe side effects and effective in only 50-60% of patients [8] . Besides that, recent research revealed that current antiviral treatment of hepatitis C therapy has poor tolerance to some patients and has a high resistance level [6, 7] . This fact indicating the search for novel antiviral agents of hepatitis C which are safer and more effective are needed. Gallic acid (1) is a naturally bioactive compound that showed antimicrobial and anti-HSV-2 activity [9, 10] . Previous researchers reported that gallic acid (1) containing in ethanolic extract of Chinese herbal Saxifraga melanocentra, showed anti-HCV activity against NS3 serine protease [11, 12] . Sharaf et al. in 2012 reported that the gallic acid which is the main component of grape seed extract of Vitis vinifera L. showed the inhibitory effect on cell growth of HCV human hepatoma HepG2 [13] . Similar with this finding, in 2014, Aoki et al. revealed that gallic acid which was isolated from Kalanchoe pinnata, a member of Crassulaceae family found in tropical areas, showed a strong anti-HCV activity [14] . Furthermore, Zuo et al. reported that ester of gallic acid and D-glucose (gallated-Dglucose ester) which has several chiral centers showed the anti-HCV activity 10 times more powerful than gallic acid or alkyl esters gallate which have no chiral center [11] . These previous results indicate that gallic acid derivative with chiral center is potential to be developed as antiviral agent of hepatitis C. Thus, in this work, we aim to synthesize gallic acid derivatives with chiral center, and to evaluate the anti-HCV activity of the derivatives against HCV.
The chemical structure of gallic acid (1) and its desired derivatives (compounds 2-5) are displayed in Fig. 1 . The synthesis was designed by modifying the carboxyl group of gallic acid with an open-chain moiety of L-threonine-allyl esters, as well as to modify hydroxyl group on the aromatic ring of gallic acid with monomethoxy group in derivative 2 and 3, and with dimethoxy group in derivative 4 and 5. To learn whether the stereochemistry affects antiviral activity, we introduce chiral center with bottom facial stereochemistry in Arsianti et al.
derivative 2 and 4, in contrast, with top facial stereochemistry in derivative 3 and 5. Introduction of a chiral center on the target derivatives is expected to increase the activity and effectiveness of the derivatives as antiviral agents of hepatitis C.
METHODS
In this research, we synthesized some derivative compounds of gallic acid with chiral center and examined its anti-HCV activity, cytotoxicity, and selectivity index (SI). Synthesis of the target derivatives was started from condensation of commercially available boc deprotection (Boc)-L-threonine with allyl bromide, followed by Boc with HCl/EtOAc and amidation reaction. Sharpless asymmetric dihydroxylation (DHQ) with OsO 4 in the presence of (DHQ) 2 PHAL or (DHQD) 2 PHAL ligand to control the stereoselectivity to give desired gallic acid derivatives with chiral center [15, 16] . The synthesis procedures of allyl ester 11 and ester 8 have been described in our previous work [17] . 1 H-nuclear magnetic resonance (NMR) and 13 C-NMR spectra were recorded on 500 MHz JEOL JNM-ECP500 spectrometers using tetramethylsilane (δ 0), CDCl 3 (δ 7.26), DMSO (δ 2.49), or acetone (δ 2.05) as an internal standard. Mass spectra were recorded on Shimadzu GCMS QP-5000 or JEOL JMS-AX 700 spectrometers.
Synthesis of amide 9
WSCD.HCl (117 mg, 0.61 mmol) and NMM (0.33 mL, 3.06 mmol) were added to a mixture solution of L-threonine-allyl-ester ammonium chloride 8 (100 mg, 0.51 mmol), monomethoxybenzoic acid 6 (130 mg, 0.61 mmol), and HOBt (104 mg, 0.77 mmol) in DMF (5 mL). The mixture was stirred at rt for 24 hrs. The mixture was then diluted by addition of EtOAc (50 mL), and washed repeatedly by water (4×25 mL), and saturated NaCl (2×25 mL). EtOAc phase was dried over MgSO 4 anhydrous and evaporated. The residue was flash chromatographed on silica gel (gradient elution 50:1 to 30:1, CHCl 3 :MeOH), gave amide 9 (96.1 mg, 58%) as yellow oil. 
Synthesis of derivative 3
To a solution of amide 9 (50 mg, 0.12 mmol), (DHQD) 2 PHAL (19 mg, 20 mol%) and NMO (72 mg, 0.6 mmol) in t-BuOH: THF:H 2 O (2:2:0.4) was added OsO 4 (6 mg, 20 mol%). The resulting mixture was stirred at rt and monitoring by TLC until disappearance of starting material 9 (1 hr). The reaction was quenched with the addition of Na 2 SO 3 (80 mg) and water (2 mL). The resulting mixture was extracted by CH 2 Cl 2 (3×15 mL). The combined CH 2 Cl 2 layers were dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. The crude residue was purified by column chromatography on silica (gradient elution 16:1 to 1:1, CHCl 3 :CH 3 OH) gave a colorless oil of derivative 3 (12.1 mg, 28% 
Synthesis of derivative 4
To a solution of amide 10 (50 mg, 0.11 mmol), (DHQ) 2 PHAL (18 mg, 20 mol%), and NMO (69 mg, 0.55 mmol) in t-BuOH: THF:H 2 O (2:2:0.4) was added OsO 4 (6 mg, 20 mol%). The resulting mixture was stirred at rt and monitoring by TLC until disappearance of starting material 10 (1 hr). The reaction was quenched with the addition of Na 2 SO 3 (80 mg) and water (2 mL). The resulting mixture was extracted by CH 2 Cl 2 (3×15 mL). The combined CH 2 Cl 2 layers were dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. The crude residue was purified by column chromatography on silica (gradient elution 40:1 to 1:1, CHCl 3 :CH 3 OH) gave a colorless oil of derivative 4 (10.3 mg, 25%). R f = 0.21 (5:1 CHCl 3 :CH 3 OH). 
Synthesis of derivative 5
To a solution of amide 10 (50 mg, 0.11 mmol), (DHQD) 2 PHAL (18 mg, 20 mol%), and NMO (69 mg, 0.55 mmol) in t-BuOH: THF:H 2 O (2:2:0.4) was added OsO 4 (6 mg, 20 mol%). The resulting mixture was stirred at rt and monitoring by TLC until disappearance of starting material 10 (1 hr). The reaction was quenched with the addition of Na 2 SO 3 (80 mg) and water (2 mL 40 (m, 1H), 4.32-4.11 (m, 3H), 3.90 (s, 3H), 3.81 (s, 3H) 
Anti-HCV activity assay
Huh7it-1 cells were seeded into 48-well plates at 5.0×10 4 cells/well 1 day before virus infection. Two-fold serial dilutions of gallic acid derivatives were prepared in culture medium in 96-well plates. The same volume of HCV (5.0×10 3 focus-forming unit) was mixed with the samples and immediately inoculated into the Huh7it-1cells. After incubation for 2 hrs at 37°C, the cells were rinsed twice with serum-free medium to remove the residual virus and incubated for an additional 46 hrs with the same medium. At 48 hrs after post infection, the culture supernatants were collected and used for virus titration.
Cytotoxicity assay
Cytotoxicity of the pure synthesized gallic acid derivatives against Huh7it-1 cells was determined using MTT assay (Sigma-Aldrich). Cells (2.0×10 4 cells/well) were seeded into 96-well plates and treated with various concentrations of the synthesized derivatives for 48 hrs. The medium was replaced with 100 µl of MTT-containing medium and incubated for an additional 4 hrs. The medium was removed, and 100 µl of DMSO was added to dissolve the generated precipitates. Absorbance at 550 nm was measured using a GloMax-Multi Microplate Multimode Reader (Promega). The percentage of viable cells was plotted versus the concentration of the test compound. The concentration by which to mediate 50% cytotoxicity (CC50) was determined by linear regression analysis.
RESULTS AND DISCUSSIONS

Synthesis of the desired derivatives (2-5)
Synthesis of the target derivatives was started from esterification of Boc-L-threonine (12) with allyl bromide to give allyl ester (11) . Boc of 11 with HCl/EtOAc afforded ester 8. In the next pathway, there are two pathways. In the first pathway, amidation of 8 with monomethoxy benzoic acid 6 to give amide 9. In the second pathway, amidation of 8 with dimethoxy benzoic acid 7, produced amide 10. Subsequently, Sharpless asymmetric DHQ of 9 with OsO4 and (DHQ) 2 PHAL ligand to give hydroxylated amide products as a 10:1 diastereomeric ratio, which can be separated by flash column chromatography to give pure derivative 2 in 30% of yield. Sharpless asymmetric DHQ of 9 with OsO4 and (DHQD) 2 PHAL followed by purification on flash column chromatography to produce pure derivative 3 in 28% of yield. Whereas, Sharpless asymmetric DHQ of 10 with (DHQ) 2 PHAL and (DHQD) 2 PHAL ligand followed by purification on flash column chromatography to produce pure derivative 4 and 5 in 25% yield and 20% yield, respectively. Monomethoxy benzoic acid 6 and dimethoxy benzoic acid 7 were prepared from starting material gallic acid by methylation with MeI/K 2 CO 3 and hydrolysis with LiOH. Synthesis pathway of target derivatives 2-5 is displayed in Scheme 1.
Antiviral activity and cytotoxicity
After completion of the synthesis, antiviral activity of gallic acid, target derivative 2, 3, 4, and 5 were evaluated against HCV strain JFH1, antiviral activity represented by IC 50 . The smaller IC 50 value, the higher antiviral activity. Toxicities of gallic acid and the derivatives against Huh 7it-1 cells were determined MTT cell proliferation assay and represented by CC50, the higher CC50, the lower cytotoxicity. Whereas, SI showed the selectivity of the test compound to inhibit the HCV infection with did not show any toxicity on the Huh-7it-1 cell (human hepatocarcinoma 7 it-1 cells). The higher SI value, more selective compound to inhibit HCV infection. Antiviral activity and cytotoxicity of gallic acid, target derivative 2,3, 4, and 5 are summarized in Table 1 .
As shown in Table 1 , gallic acid, derivative 2 and 3 have CC 50 value over than 100 µg/mL which are assigned as nontoxic compounds, whereas derivative 4 and 5 with a CC 50 value of 18.3 and 27.2 μg/mL, respectively, are assigned as toxic compounds. This result is suggesting that replacing two hydroxyl groups of gallic acid with methoxy groups will increase the cytotoxicity. Compared to gallic acid (1), antiviral activity and SI of derivative 2 and 3 are greatly improved by the presence of chiral center, hydroxyl group, and monomethoxy group on the aromatic ring. This fact suggested that the chiral center, hydroxyl group, and monomethoxy group on the aromatic ring are very important for selectivity and anti-HCV activity. Furthermore, derivative 2 which contains hydroxyl group with bottom facial stereochemistry on the chiral center, showed a higher selectivity and stronger anti-HCV activity compared to derivative 3 which has hydroxyl group with top facial stereochemistry on the chiral center, suggesting that bottom facial stereocenter in derivative 2 was more effective for anti-HCV activity than top facial stereocenter in derivative 3. 
CONCLUSION
Gallic acid derivatives with chiral center have been synthesized. The target derivatives exhibited a greater antiviral activity against HCV than gallic acid. Thus, the derivatives of gallic acid with chiral center should be considered as a promising candidate for the treatment of HCV infection. 
